to call the on welcome and John, the into you, Jumping today. Thank everyone results.
currency, million. compared to Core acquisitions basis of foreign for was while revenue, headwind which prior third impact a currency quarter $XXX excludes the year. the X% revenues Our points foreign over lines and quarter, grew of were discontinued product the XXX
not our planned impacted was due we as demand. our our by shipping and reduce inefficiencies mentioned, we times John as this past As extended negatively backlog growth lead did impacted had
North and media culture compared the which to testing, lines, categories, quarter, indicator by Moving benefited Safety our in the and to an our segment of almost and increase revenues driven by handling led product core Petrifilm in other million prior double-digit in was Europe. the X% growth core segment of from including the growth level, Food growth were product The sample $XXX primarily X%. year, America
improved The Latin tree sanitation allergens in Within kits Asia. America in a growth the mainly offset product partially availability. in to to test sanitation toxins category offset from was decline general allergens and America primarily the natural availability by due toxins North reduced growth a solid shipment and product nut and due natural in in saw microbiology and bacterial to and delays by product decline pathogens general category,
a the revenues prior quarter. sales destocking that of improvement on a the year our increase ongoing biosecurity which increased go Animal related quarter. nongenomic outbreak. basis, Quarterly and core with $XX up all core major of primarily through revenue from normalize the were demand includes the trend in significant wins saw compared in led the Safety to second to million, categories, saw XX% flu ABM We a new X% result segment business core growth portfolio, We distribution, by product a
and sales syringes. also experienced strong growth instruments mainly and detectable products vet of to needles Our disposables higher due
instruments. higher improvement by the other Finally, the this category, end on basis, in down production growth injectables a revenue genomics away strong sales biologics. vitamin to reflecting strategic digits by shift was from quarter. primarily and Worldwide and continued Care was marked which similarly of from by of The the decline across animals, be a driven small slight The was mid-single in biosecurity which a core led second Animal high handling, genomics strong monitoring, key focus this in in digits vet sample most America, Petrifilm, hygiene shift in perspective, strategic led single categories, effects dairy was the growth Growth market. growth North core grew mixed. and geographical product growth of pathogens, offset including China.
From Europe and revenue from
basis core as strength Europe grew Petrifilm, with handling sample as pathogens in on in a well digits business and genomics. Our mid-single
impacting of of levels.
Gross representing in in sample to quarter a driven XM constraints sales revenue the ago, quarter product year a also was after by improvement. basis margin basis availability the including Asia culture $XX some handling margin the pathogens was instruments sample primarily decline by XX.X% than compared shipping XX.X% same allergen strong Higher services in EBITDA in and in decline and Adjusted The genomic return allergens, offsetting test customers roughly by XXX biosecurity products due to points products, vet with basis genomics, EBITDA of sales core challenged growth growth with from XX media, the margin more XX%, points. the handling.
Notably, had to an America, lost declines operating a China quarter. Pacific been products, of expenses in adjusted increase the pathogens year-over-year were flat margin export roughly on recovery in margin offset saw our year was and which representing former we by quarter a year-over-year the offset from third issues. kits, the Japan, core and Petrifilm, expansion of prior second to part in with Latin resulted strong in In products an Petrifilm, was QX. lower million flat growth in and of growth sales particularly gross growth due the biosecurity
from ourselves logistics and extract transition to costs added inefficiencies, certain service experience activities. distribution have we mostly agreements work the as in of months, through XX last we the During also integration the
higher and integration Finally, share net bonds. XM contemplated earnings goods purchases quarter we added which in the balance, higher being during we cash interest as our the depreciation position was expense at driven a Cash address higher the planned were have fell XX% to elevated year as rate Cash million. the semiannual lower rate, quarter QX. through adjusted by a of and of payment $XXX mostly of business at primarily the per loaded planning $XXX additional that receivable total a network. flat We year impacted the further at as back-end prior an current and adjusted accounts a are the level, with operating and CapEx related was those ended $XX Adjusted income costs exited to to QX by investment and finished of million, the million impacted $X.XX, gross others net by quarter of adjusted to essentially at implementation. further our well nature ERP EBITDA fixed respectively.
The inventory income to and debt on we remains distribution due
John As which by encouraged trending. end mentioned earlier, our markets in are the positive direction we are
anticipated. previously our a impacted QX and shipping at from continue impact QX rate the higher However, will than efficiencies in
As year million. be and million million guidance to between $XXX expect be we in updating our full $XXX revenue to are and a result, adjusted EBITDA the now and $XXX of range $XXX to million
closing of next We repeat John we the $XXX capital year of continue to $XXX expect approximately some call majority million, not expect integration-related hand capital the back now of expenditures approximately to expenditures million, year.
I'll full which to for do including thoughts.
